10-K: DENTSPLY SIRONA Inc. Reports Full Year 2024 Results, Cites Goodwill and Intangible Asset Impairments

DENTSPLY SIRONA Inc. reports a net loss for 2024, impacted by significant goodwill and intangible asset impairment charges, despite increased cash from operations.

Summary

• DENTSPLY SIRONA Inc. reported a net loss of $910 million for the year ended December 31, 2024, compared to a net loss of $132 million in the prior year.
• The diluted loss per share was $4.48, compared to a diluted loss per share of $0.62 in the prior year.
• Net sales decreased by 4.3% compared to the prior year, with organic net sales decreasing by 3.5%.
• The company's performance was negatively impacted by a 0.8% due to the strengthening of the U.S. dollar.
• Cash from operations increased to $461 million, compared to $377 million in the prior year.
• The company experienced higher goodwill and intangible asset impairment charges of $1,014 million compared to $307 million in the prior year.
• The company is implementing a restructuring plan expected to yield $80 million to $100 million in annual cost savings.
• The company is evaluating strategic alternatives for its Wellspect Healthcare business.
• The company voluntarily suspended the sale and marketing of its direct-to-consumer Byte aligner systems and impression kits, and subsequently determined to cease offering these aligners to new patients while repurposing Byte technologies and capabilities to support other products within our aligner portfolio.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant losses and impairment charges, offset slightly by increased cash from operations and restructuring efforts. The overall tone suggests challenges and uncertainty.

Positives

• Cash from operations increased to $461 million.
• The company's restructuring plan is expected to result in $80 million to $100 million in annual cost savings.
• The company has $1.2 billion remaining under its share repurchase program.
• The company has $313 million of borrowings available under lines of credit.

Negatives

• DENTSPLY SIRONA Inc. reported a net loss of $910 million for the year ended December 31, 2024.
• Organic net sales decreased by 3.5% for the year ended December 31, 2024.
• The company incurred $1,014 million in goodwill and intangible asset impairment charges.
• The company voluntarily suspended the sale and marketing of its direct-to-consumer Byte aligner systems and impression kits, and subsequently determined to cease offering these aligners to new patients while repurposing Byte technologies and capabilities to support other products within our aligner portfolio.

Risks

• The company faces risks related to cyber incidents, evolving data privacy regulations, and the ability to develop innovative products.
• Damage to the company's reputation or brand could negatively impact its business.
• The company may be unable to execute key strategic initiatives due to competing priorities of distribution partners.
• The company may fail to realize the expected benefits of its strategic initiatives.
• The company's financial results may be adversely impacted if its products infringe upon the intellectual property rights of others.
• Changes in credit ratings or macroeconomic impacts on credit markets may increase the company's cost of capital.
• The company's business may be adversely affected by changes in global economic conditions, including inflation and supply chain shortages.
• The company may be subject to additional litigation and regulatory examinations relating to past financial reporting matters.
• The company may be unable to obtain necessary product approvals and marketing clearances.
• The company voluntarily suspended the sale and marketing of its direct-to-consumer Byte aligner systems and impression kits, and subsequently determined to cease offering these aligners to new patients while repurposing Byte technologies and capabilities to support other products within our aligner portfolio.
• The company's business is subject to extensive, complex, and changing domestic and foreign laws and regulations.

Future Outlook

The company expects a continuation of inflationary pressure on the cost of both raw materials and wages into 2025. The company anticipates that the challenging macroeconomic and market conditions in Germany are likely to persist and negatively impact sales of equipment into next year.

Management Comments

• The company is focused on maximizing operational excellence on a global basis.
• The company has expanded the use of technology and has undertaken process improvement initiatives to enhance global efficiency.
• Management continues to evaluate the worldwide consolidation and simplification of operations and functions to further reduce costs.
• The company intends to continue pursuing opportunities to expand the company's product and solutions offerings, technologies, and sales and service infrastructure through partnerships.

Industry Context

The dental industry is experiencing consolidation, price competition, and increasing demand for digital solutions. The company is facing competitive pressures from lower-cost alternatives and macroeconomic challenges affecting demand for elective procedures.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• The document does not provide specific project comparisons or results.

Legal Proceedings

• The company is involved in several legal proceedings, including securities class action lawsuits and a stockholder derivative suit.
• The company is under audit in Germany for the tax years 2014 through 2021.
• The company is contesting a proposed adjustment from the IRS related to an internal reorganization completed in 2016.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and decline in stock price.
• Employees may be affected by the restructuring plan and potential workforce reductions.
• Customers may experience changes in product offerings and distribution channels.
• Suppliers may be affected by changes in sourcing and procurement strategies.

Next Steps

• The company will continue to implement its restructuring plan to improve operational performance and drive stockholder value creation.
• The company will continue to evaluate strategic alternatives for its Wellspect Healthcare business.
• The company will continue to monitor and evaluate the potential impact of tariffs and changes in foreign trade policy.
• The company will continue to monitor developments and prepare contingency plans to limit potential disruption to its operations in Israel.

Key Dates